Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Net Margin (2016 - 2025)

Guided Therapeutics' Net Margin history spans 15 years, with the latest figure at 1308.33% for Q3 2025.

  • For Q3 2025, Net Margin changed N/A year-over-year to 1308.33%; the TTM value through Sep 2025 reached 367.42%, up 584311.0%, while the annual FY2024 figure was 6300.0%, 246429.0% down from the prior year.
  • Net Margin for Q3 2025 was 1308.33% at Guided Therapeutics, down from 731.62% in the prior quarter.
  • Across five years, Net Margin topped out at 145000.0% in Q4 2024 and bottomed at 64950.0% in Q2 2021.
  • The 5-year median for Net Margin is 3645.45% (2023), against an average of 1254.8%.
  • The largest annual shift saw Net Margin plummeted -3483158bps in 2022 before it skyrocketed 14646562bps in 2024.
  • A 5-year view of Net Margin shows it stood at 848.33% in 2021, then crashed by -4038bps to 35100.0% in 2022, then soared by 96bps to 1465.62% in 2023, then soared by 9993bps to 145000.0% in 2024, then tumbled by -101bps to 1308.33% in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Net Margin are 1308.33% (Q3 2025), 731.62% (Q2 2025), and 145000.0% (Q4 2024).